ViaCell, a biotechnology firm developing stem cell based therapeutics to treat cancers, withdrew its IPO on the last day of the year, citing unfavorable market conditions. UBS Investment Bank was expected to take the Boston, MA based company public.
ViaCell, a biotechnology firm developing stem cell based therapeutics to treat cancers, withdrew its IPO on the last day of the year, citing unfavorable market conditions. UBS Investment Bank was expected to take the Boston, MA based company public.